An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension

NCT ID: NCT00825396

Last Updated: 2009-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

C-KAD Ophthalmic Solution

Group Type EXPERIMENTAL

C-KAD Ophthalmic Solution

Intervention Type DRUG

4 drops applied daily for 150 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

C-KAD Ophthalmic Solution

4 drops applied daily for 150 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both eyes having intraocular pressure in the range of 22-30 mmHg at baseline
* Both eyes having best corrected visual acuity better than 20/50

Exclusion Criteria

* Advanced glaucoma
* Closed or barely open anterior chamber or history of angle closure
Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chakshu Research, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chakshu Research, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ira Wong, MD

Role: STUDY_DIRECTOR

Chakshu Research, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charlotte Eye, Ear, Nose & Throat Associates

Charlotte, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PCK-0106

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Soothe Versus Refresh
NCT00284999 COMPLETED PHASE4